Published online before print February 16, 2006, doi: 10.1161/01.RES.0000214553.37930.3e
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 22, 2005
Revised on February 3, 2006
Accepted on February 8, 2006
De Novo Synthesis of Cyclooxygenase-1 Counteracts the Suppression of Platelet Thromboxane Biosynthesis by Aspirin
Virgilio Evangelista ;
From the Consorzio Mario Negri Sud (V.E., S.M., A.DS., S.D.), Santa Maria Imbaro, "Gabriele d’Annunzio" University and Foundation (M.L.C., E.R., L.DF., S.T., A. Sacchetti, M.G.S., P.P.), and Ce.S.I., Chieti, University of Bari (A. Scilimati), Italy.
* To whom correspondence should be addressed. E-mail: ppatrignani{at}unich.it.
Aspirin affords cardioprotection through the acetylation of serine529 in human cyclooxygenase-1 (COX-1) of anucleated platelets, inducing a permanent defect in thromboxane A2 (TXA2)-dependent platelet function. However, heterogeneity of COX-1 suppression by aspirin has been detected in cardiovascular disease and may contribute to failure to prevent clinical events. The recent recognized capacity of platelets to make proteins de novo paves the way to identify new mechanisms involved in the variable response to aspirin. We found that in washed human platelets, the complete suppression of TXA2 biosynthesis by aspirin, in vitro, recovered in response to thrombin and fibrinogen in a time-dependent fashion (at 0.5 and 24 hours, TXB2 averaged 0.1±0.03 and 3±0.8 ng/mL; in the presence of arachidonic acid [10 µmol/L], it was 2±0.7 and 25±7 ng/mL, respectively), and it was blocked by translational inhibitors, by rapamycin, and by inhibitors of phosphatidylinositol 3-kinase. The results that COX-1 mRNA was readily detected in resting platelets and that [35S]-methionine was incorporated into COX-1 protein after stimulation strongly support the occurrence of de novo COX-1 synthesis in platelets. This process may interfere with the complete and persistent suppression of TXA2 biosynthesis by aspirin necessary for cardioprotection.
This article has been cited by other articles:
 |
|
 |
|
  B. Jespersen, H. C. Thiesson, C. Henriksen, K. Therland, C. Falk, T. Poulsen, B. Fogh, K. Madsen, S. Walther, and B. L. Jensen Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1644 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Santilli, B. Rocca, R. De Cristofaro, S. Lattanzio, L. Pietrangelo, A. Habib, C. Pettinella, A. Recchiuti, E. Ferrante, G. Ciabattoni, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays implications for aspirin "resistance". J. Am. Coll. Cardiol., February 24, 2009; 53(8): 667 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brambilla, M. Camera, D. Colnago, G. Marenzi, M. De Metrio, P. L. Giesen, A. Balduini, F. Veglia, K. Gertow, P. Biglioli, et al. Tissue Factor in Patients With Acute Coronary Syndromes: Expression in Platelets, Leukocytes, and Platelet-Leukocyte Aggregates Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 947 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Zimmerman and A. S. Weyrich Signal-Dependent Protein Synthesis by Activated Platelets: New Pathways to Altered Phenotype and Function Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s17 - s24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Maree and D. J. Fitzgerald Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease Circulation, April 24, 2007; 115(16): 2196 - 2207. [Full Text] [PDF]
|
|